Why the study?
Activated fibroblasts drive pathological fibrosis and repair, but despite phenotypic heterogeneity, they are not recognized as distinct functional entities.
Identifies a functionally distinct, pro-angiogenic FSP1-positive fibroblast subtype in post-MI mouse hearts, highlighting fibroblast heterogeneity in wound healing and fibrosis.
Two fibroblast subtypes distinguished in fibrosis; hypothesis-generating for selective targeting, pending in vivo validation.
Fibrosis accompanying wound healing can drive the failure of many different organs. Activated fibroblasts are the principal determinants of post-injury pathological fibrosis along with physiological repair, making them a difficult therapeutic target. Although activated fibroblasts are phenotypically heterogeneous, they are not recognized as distinct functional entities. Using mice that express GFP under the FSP1 or αSMA promoter, we characterized two non-overlapping fibroblast subtypes from mouse hearts after myocardial infarction. Here, we report the identification of FSP1-GFP + cells as a non-pericyte, non-hematopoietic fibroblast subpopulation with a predominant pro-angiogenic role, characterized by in vitro phenotypic/cellular/ultrastructural studies and in vivo granulation tissue formation assays combined with transcriptomics and proteomics. This work identifies a fibroblast subtype that is functionally distinct from the pro-fibrotic αSMA-expressing myofibroblast subtype. Our study has the potential to shift our focus towards viewing fibroblasts as molecularly and functionally heterogeneous and provides a paradigm to approach treatment for organ fibrosis.
No takes yet. Share an insight, caveat, or question.
Saraswati et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: